Page 2 - Bringing Value News Today : Breaking News, Live Updates & Top Stories | Vimarsana

For an industry in critical condition, failure to pivot to a new model is not optional: for better or worse, the next catalyst for change is coming.

Long standing economic, operational and other challenges will persist into 2024, with the net of these forces raising the need to pivot to a new patient-centered model.

The pharma landscape is more volatile than ever before, and pushback on drug prices will continue to intensify from payers, PBMs and especially consumers.

There is no easy fix to get us to a new market-based model in healthcare, but greater transparency must be the centerpiece of any reform.

Without a focused effort to clearly make the case for the true value of medicines and drug innovation, consumers' negative perceptions about the industry will persist.